BACKGROUND: We describe here, a whole-body imageable spontaneous metastatic model of human prostate cancer developed by surgical orthotopic implantation (SOI) and visualized by red fluorescent protein (RFP) expression. METHODS: Human prostate cancer PC-3 cells were transduced with the pLNCX2-DsRed-2-RFP retroviral vector containing the RFP and neomycin-resistance genes. A stable RFP-expressing PC-3 clone was selected in 800 microg/ml G418 in vitro and injected subcutaneously in nude mice. Stable high-level expression of RFP was maintained in the subcutaneously-growing tumors. To utilize RFP expression for metastasis studies, fragments of the subcutaneously-growing tumor, which were comprised of RFP-expressing cells, were implanted by SOI in the prostate of nude mice. RESULTS: Primary tumor growth, progression, and subsequent lymphatic metastases were visualized in live, intact animals in real time by whole-body RFP fluorescence imaging. In total, 100% of the experimental animals developed lymphatic metastasis, the growth of which was monitored in real time by whole-body imaging. The aggressive lymphatic metastasis in this model reflects one of the major metastatic routes of prostate cancer in human patients. Intravital RFP imaging visualized single cancer cells in the lung and bladder. Open RFP imaging at autopsy visualized extensive primary growth and highly disseminated lymph-node metastases. CONCLUSIONS: The long-wavelength emission of RFP enabled high sensitivity and resolution of microscopic tumor growth using appropriate imaging techniques. The model should be useful for the real-time evaluation of novel therapeutics for metastatic prostate cancer.
BACKGROUND: We describe here, a whole-body imageable spontaneous metastatic model of humanprostate cancer developed by surgical orthotopic implantation (SOI) and visualized by red fluorescent protein (RFP) expression. METHODS:Humanprostate cancer PC-3 cells were transduced with the pLNCX2-DsRed-2-RFP retroviral vector containing the RFP and neomycin-resistance genes. A stable RFP-expressing PC-3 clone was selected in 800 microg/ml G418 in vitro and injected subcutaneously in nude mice. Stable high-level expression of RFP was maintained in the subcutaneously-growing tumors. To utilize RFP expression for metastasis studies, fragments of the subcutaneously-growing tumor, which were comprised of RFP-expressing cells, were implanted by SOI in the prostate of nude mice. RESULTS:Primary tumor growth, progression, and subsequent lymphatic metastases were visualized in live, intact animals in real time by whole-body RFP fluorescence imaging. In total, 100% of the experimental animals developed lymphatic metastasis, the growth of which was monitored in real time by whole-body imaging. The aggressive lymphatic metastasis in this model reflects one of the major metastatic routes of prostate cancer in humanpatients. Intravital RFP imaging visualized single cancer cells in the lung and bladder. Open RFP imaging at autopsy visualized extensive primary growth and highly disseminated lymph-node metastases. CONCLUSIONS: The long-wavelength emission of RFP enabled high sensitivity and resolution of microscopic tumor growth using appropriate imaging techniques. The model should be useful for the real-time evaluation of novel therapeutics for metastatic prostate cancer.
Authors: Rira Watanabe; Kazuhide Sato; Hirofumi Hanaoka; Toshiko Harada; Takahito Nakajima; Insook Kim; Chang H Paik; Anna M Wu; Peter L Choyke; Hisataka Kobayashi Journal: ACS Med Chem Lett Date: 2014-01-17 Impact factor: 4.345
Authors: Christian M Zechmann; Eva C Woenne; Gunnar Brix; Nicole Radzwill; Martin Ilg; Peter Bachert; Peter Peschke; Stefan Kirsch; Hans-Ulrich Kauczor; Stefan Delorme; Wolfhard Semmler; Fabian Kiessling Journal: Neoplasia Date: 2007-01 Impact factor: 5.715
Authors: Ming Zhao; Jack Geller; Huaiyu Ma; Meng Yang; Sheldon Penman; Robert M Hoffman Journal: Proc Natl Acad Sci U S A Date: 2007-06-04 Impact factor: 11.205
Authors: A Mavrou; K Brakspear; M Hamdollah-Zadeh; G Damodaran; R Babaei-Jadidi; J Oxley; D A Gillatt; M R Ladomery; S J Harper; D O Bates; S Oltean Journal: Oncogene Date: 2014-11-10 Impact factor: 9.867
Authors: Weg M Ongkeko; Doug Burton; Alan Kiang; Eric Abhold; Selena Z Kuo; Elham Rahimy; Meng Yang; Robert M Hoffman; Jessica Wang-Rodriguez; Leonard J Deftos Journal: PLoS One Date: 2014-01-22 Impact factor: 3.240